Literature DB >> 22459268

Response to "Ipilimumab (Yervoy) and the TGN1412 catastrophe".

Michael A Curran, Margaret K Callahan, Sumit K Subudhi, James P Allison.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22459268     DOI： 10.1016/j.imbio.2011.11.001

Source DB:  PubMed          Journal:  Immunobiology        ISSN： 0171-2985            Impact factor:   3.144


× No keyword cloud information.
  2 in total

Review 1.  Hostile, hypoxia-A2-adenosinergic tumor biology as the next barrier to overcome for tumor immunologists.

Authors:  Michail V Sitkovsky; Stephen Hatfield; Robert Abbott; Bryan Belikoff; Dmitriy Lukashev; Akio Ohta
Journal:  Cancer Immunol Res       Date:  2014-07       Impact factor: 11.151

2.  Low-dose ipilimumab plus nivolumab combined with IL-2 and hyperthermia in cancer patients with advanced disease: exploratory findings of a case series of 131 stage IV cancers - a retrospective study of a single institution.

Authors:  R Kleef; R Nagy; A Baierl; V Bacher; H Bojar; D L McKee; R Moss; N H Thoennissen; M Szász; T Bakacs
Journal:  Cancer Immunol Immunother       Date:  2020-11-05       Impact factor: 6.968
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.